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Trends
Antimalarial drugs are being used in
many different contexts beyond treat-
ment of disease – increasingly with the
aim of reducing malaria transmission in
a community.
Each drug has different attributes – kill-
ing efﬁcacy against asexual parasites,
duration of effect, gametocytocidal
activity, mosquitocidal activity, liver-
stage activity (for Plasmodium vivax),
dosing schedule and toxicity.
Drug attributes need to be rationally
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Mathematical models of the dynamics of a drug within the host are now
frequently used to guide drug development. These generally focus on assessing
the efﬁcacy and duration of response to guide patient therapy. Increasingly,
antimalarial drugs are used at the population level, to clear infections, provide
chemoprevention, and to reduce onward transmission of infection. However,
there is less clarity on the extent to which different drug properties are important
for these different uses. In addition, the emergence of drug resistance poses
new threats to longer-term use and highlights the need for rational drug devel-
opment. Here, we argue that integrating within-host pharmacokinetic and
[22_TD$DIFF]pharmacodynamic (PK/PD) models with mathematical models for the popula-
tion-level transmission of malaria is key to guiding optimal drug design to aid
malaria elimination.combined to match their usage aims
based on a quantitative understanding
of their properties.
For transmission reductions, the indivi-
dual patient approach is less relevant
and a population-level perspective is
critical.
Rational approaches to combining
drugs with other forms of malaria con-
trol to reduce malaria transmission can
only be made using transmission mod-
els informed by ﬁeld data, given the
difﬁculty of testing all combinations of
interventions in all settings.Extended Role of Drugs for Malaria Control and Elimination
Over the [23_TD$DIFF]past 15 years, declines in malaria transmission have been witnessed across many
malaria-endemic countries, with a 37% fall in case incidence and 60% drop in mortality rates
between 2000 and 2015 [1]. Whilst much of the progress to date has been attributed to
enhanced vector control [2], there has recently been increased interest in the role that drug-
based strategies that extend beyond ﬁrst-line treatment of malaria cases could play in further
reducing morbidity and mortality and in moving towards malaria elimination. This includes the
role of enhanced case-ﬁnding, wider chemoprevention (see Glossary) strategies to protect
high-risk groups and mass treatment strategies to clear the infectious reservoir [3]. However,
at the same time the emergence of resistance to artemisinin drugs and to artemisinin
combination therapies (ACT) [4–6] (as well as to other components of the malaria arsenal
such as insecticides) has demonstrated the potential fragility of current strategies. Here we argue
that transmission modelling can provide a unique population-level perspective to guide the
development of new antimalarial drugs to ensure that they are tailored for speciﬁc usage
scenarios.1MRC Centre for Outbreak Analysis &
Modelling, Department of Infectious
Disease Epidemiology, Imperial
College London, UK
*Correspondence:
a.ghani@imperial.ac.uk (A.C. Ghani).Antimalarial Drug Properties and Malaria Transmission
The objective and purpose of antimalarial drugs, in common with other anti-infectives, has
traditionally been to clear infection in an individual. Thus, during the drug development process,
the central focus is on the ability of the compound to kill the parasite during the blood stage of
infection or on providing chemoprevention to high-risk groups [7–9].
Mathematical models are frequently employed at this stage to guide product development
[10,11]. These models incorporate two factors. The ﬁrst is the pharmacokinetics of the
compound: how the drug concentration increases and decays over time as determined byTrends in Parasitology, Month Year, Vol. xx, No. yy http://dx.doi.org/10.1016/j.pt.2016.09.004 1
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
TREPAR 1557 No. of Pages 10
Glossary
Amodiaquine: partner drug for ﬁrst-
line treatment; also used as part of
recommended regimen for seasonal
malaria chemoprevention (SMC).
Anopheles: species of mosquito
responsible for transmission of the
malaria parasite.
Artemisinin: a class of drugs,
isolated from the plant Artemisa
annua, which provide rapid action
against P. falciparum infection.
Artemisinin combination therapy
(ACT): a combination of an
artemisinin derivative with a longer-
acting antimalarial drug that has a
different mode of action.
Asexual parasite: collective term for
the parasite forms during the blood-
stage infection that invade the red
blood cells and distinguish from the
infectious form (gametocyte).
Atovaquone: partner drug for ﬁrst-
line treatment; also used for
chemoprophylaxis.
Chemoprevention: intermittent
administration of a full treatment
course of an antimalarial medicine to
prevent malarial illness.
Chemoprophylaxis: administration
of a medicine, at predeﬁned intervals,
to prevent either the development of
an infection or progression of an
infection to manifest disease.
Chloroquine: early drug used for
ﬁrst-line treatment prior to the
widespread development of
resistance from the 1990s onwards.
Endectocide: an antiparasitic drug
that is active against both
endoparasites and ectoparasites.
Gametocyte: sexual stage of malaria
parasites that can potentially infect
Anopheles mosquitoes when
ingested during a blood meal. This
stage plays no role in clinical disease
and hence was not initially a focus for
drug developers.
Hypnozoite: persistent liver stage of
P. vivax (and P. ovale) malaria that
remains dormant in host hepatocytes
for variable periods before activation
and development into a pre-
erythrocytic schizont which then
causes a blood-stage infection
(relapse).
IC50: the concentration of a drug
that is needed to give half of its
maximal biological efﬁcacy.
Infectious reservoir: the product of
the number of people harbouring
parasites that can be transmitted on
to mosquitoes and their relative
infectiousness.its absorption, distribution, metabolism, and excretion. This is typically described by a set of
differential equations, broadly representing the physical compartments where these different
effects take place. The second is the pharmacodynamics, describing the relationship between
the drug concentration and its killing efﬁcacy. This is summarised as a ‘ [24_TD$DIFF]dose [25_TD$DIFF]response curve’
showing the efﬁcacy as a function of the measured concentration in the blood. By combining
these two models, predictions can be made of the likely efﬁcacy and its decay over time for
different dosing schedules. Such approaches are increasingly being evaluated to inform anti-
malarial drug development, including optimising the dosing schedule [12–15], and to explore the
impact of combinations of therapies [16–19].
A key property of the current artemisinin-based therapies is their additional effect on the
gametocyte stage of the parasite, which is responsible for onward transmission to the
mosquito [20,21]. Once patent blood-stage infection is established, gametocytes develop from
asexual parasites with the delay due to maturation of approximately 10 days in Plasmodium
falciparum infection, and hence, following treatment, if [26_TD$DIFF]the [27_TD$DIFF]drug has no gametocytocidal activity,
an individual may remain infectious for 20–50 days [22,23]. The gametocytocidal activity of
compounds is known to differ, with most current artemisinin [28_TD$DIFF] compounds having high efﬁcacy
against the early stages and thus reducing the post-treatment infectious period to between 10
and 20 days [22,24,25]. However, some compounds, including primaquine and tafenoquine,
attack the later gametocyte stages which reduces the post-treatment infectious period to 0–10
days [26–28]. Whilst such properties were historically not a focus of the drug development
agenda, their potential for clearing infection has more recently been recognised, and there is an
active research agenda into the potential utility of drugs with higher levels of gametocytocidal
activity [29–31].
In Plasmodium vivax, there is no lag between blood-stage infection and the development of
gametocytes. However, treatment for P. vivax differs to that for P. falciparum due to the
presence of a hypnozoite reservoir in the liver, which is not affected by ACTs. One class of
drugs – the 8-aminoquinolines – is effective against this form, with primaquine (given as a 14-day
full-dose course in contrast to its use at single low-dose for gametocyte clearance in P.
falciparum infection) currently the only drug available from this class for treatment [8]. The ability
to clear this reservoir of dormant infection has beneﬁts for both the individual (in preventing
relapses of disease) and for population-level transmission.
Whilst the efﬁcacy of [14_TD$DIFF]any [29_TD$DIFF]antimalarial against asexual parasites and gametocytes (and for P.
vivax, hypnozoites) determines the clearance rate of infection and onward infectivity in the
individual, the relative value of these different drug actions at the population level can only be
assessed by considering who in the population is transmitting infection. This infectious
reservoir combines both those who present with clinical disease (and hence who may
potentially seek treatment) and asymptomatic carriers of infection [32–35].
Figure 1 shows a hypothetical typical course of infection in these individuals and the likely
reduction in onward infectivity at the population level from increasing gametocytocidal activity. It
is clear from this simple schematic that clearance of asexual parasites has the greatest effect in
reducing onward infectivity (as by killing asexual parasites, fewer gametocytes develop), whilst
the additional beneﬁts of gametocytocidal activity may be modest. A number of mathematical
models have quantiﬁed this effect in different transmission settings [23,36–39]. Despite using
very different model frameworks, there is clear consensus that artemisinin-based therapies have
some advantage over non-artemisinin based therapies in reducing onward transmission, in
particular in areas in which a high proportion of infections seek care [23,40]. Furthermore, there is
clear consensus that additional gametocytocidal activity, as provided for example by low-dose
primaquine, will have negligible additional impact [23,36,38,39]. This is in contrast to the results2 Trends in Parasitology, Month Year, Vol. xx, No. yy
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Intermittent preventive treatment
in pregnancy (IPTp): a full
therapeutic course of antimalarial
medicine given to pregnant women
at routine prenatal visits, regardless
of whether the woman is infected
with malaria.
Ivermectin: mosquitocidal drug
currently used to treat
onchocerciasis.
Lumefantrine: partner drug for ﬁrst-
line treatment.
Mass drug administration:
administration of antimalarial
treatment to every member of a
deﬁned population or living in a
deﬁned geographical area (except
those for whom the medicine is
contraindicated) at approximately the
same time and often at repeated
intervals.
Meﬂoquine: partner drug for ﬁrst-line
treatment; also used for
chemoprophylaxis.
Mosquitocidal: a drug or compound
that kills mosquitoes.
Multiple ﬁrst-line therapy (MFT): a
policy to administer more than one
antimalarial combination for ﬁrst-line
treatment at a population level; this
can be geographically stratiﬁed or
individually randomised.
Parasite reservoir: people
harbouring parasites, regardless of
their onward infectivity.
Partner drug: a longer-acting
antimalarial drug given in combination
with an artemisinin drug that has a
different mode of action.
Pharmacodynamics: the
biochemical and physiological effects
of drugs and their mechanism of
action.
Pharmacokinetics: the absorption
and distribution of drugs through the
body.
Piperaquine: partner drug for ﬁrst-
line treatment; used for prophylaxis in
China and India prior to the
development of resistance.
Primaquine: the only licensed drug
for treatment of Plasmodium vivax
hypnozoites. Also recommended at
low-dose for clearance of
gametocytes in Plasmodium
falciparum infections in areas with low
transmission.
Prophylaxis: any method of
protection from or prevention of
disease.
Relapse infection: recurrence of
asexual parasitaemia in P. vivax or P.
ovale infections arising from
hypnozoites.obtained using an individual-patient approach [28,41], and highlights the need to use models to
evaluate impact at the population level.
A promising new avenue of research for antimalarial compounds ismosquitocidal activity. This
has been stimulated by the recent identiﬁcation of the potential for ivermectin (one of a number
of endectocide compounds) to reduce the lifespan of a mosquito which ingests the compound
from the blood of a treated individual. This can have two effects; ﬁrst, it could reduce the
probability that parasites ingested during the blood meal reach their infectious sporozoite
stage, and secondly, it can act directly as vector control by reducing the Anopheles population.
Whilst initially, focus was on the ﬁrst effect, mathematical modelling has demonstrated that, at a
population level, the second effect is likely to be dominant [39,42]. Thus, perhaps for the ﬁrst time
in antimalarial drug development, modelling is being integrated into the wider research agenda to
inform the evaluation of ivermectin as a tool to aid malaria elimination [43].
Expanding the Use of Antimalarial Drugs
The primary use of antimalarial drugs is the treatment of symptomatic cases. For this purpose,
the most important properties are effective clearance of parasites and quick alleviation of
symptoms. However, by taking a population perspective, the relative importance of various
drug properties in different settings can be disentangled (Table 1, Key Table).
In moderate to high transmission settings, modelling has demonstrated that drugs with longer
durations can have important additional beneﬁt for the individual by providing a period of
prophylaxis and hence reducing rates of reinfection [40,44–46]. [30_TD$DIFF]By contrast, the gametocy-
tocidal and mosquitocidal effects are predicted to be limited [23,36–39]. This is because the
proportion of the total infectious reservoir that is being treated is very small – the majority of
onward transmission will be from asymptomatic (yet infectious) individuals who are not receiving
treatment (Figure 1). [30_TD$DIFF]By contrast, in a low-transmission setting, individuals with clinical disease
seeking treatment will constitute a larger proportion of the infectious reservoir (Figure 1). In these
settings gametocytocidal and mosquitocidal effects will have a greater proportionate impact.
Furthermore, the duration of prophylaxis will become less important as transmission declines
since the risk of reinfection also becomes low. For P. vivax, modelling has shown that, in all
settings, treatments that attack the hypnozoites are critical to reduce transmission of the
parasite at the population level [47–50].
Drugs are also used for chemoprophylaxis (for visiting travellers) and chemoprevention (for
those residing in endemic areas). In both scenarios, the aim is to provide protection against
infection for short periods of time to at-risk groups. Seasonal malaria chemoprevention
(SMC) was recommended by the WHO in 2012 as a 3-month course of drugs given to children
under 5 years in areas with highly seasonal transmission (the Sahel region of Africa) (http://www.
who.int/malaria/publications/atoz/who_smc_policy_recommendation/en/). A key property of
the drug is its ability to prevent infection and, for this use, modelling has demonstrated the
superiority of long-acting combinations [44]. One concern about SMC has been the potential
delay of the acquisition of immunity and hence a shifting of malaria cases to older ages which
could potentially result in an increase in total cases or increased severity of disease [51]. Whilst
this has been difﬁcult to assess in individuals, the population effect has been suggested, by
modelling studies, to be potentially large [52–54].
Chemoprevention is also recommended in pregnant women residing in endemic areas, through
intermittent preventive treatment in pregnancy (IPTp). Here the aim is to prevent seques-
tration of the parasite in the placenta by clearing infection in both the placenta and circulating
blood, and hence reducemorbidity in the mother and baby [55]. Whilst the focus has traditionally
been on the second and third trimesters, modelling has demonstrated that the highest risk is theTrends in Parasitology, Month Year, Vol. xx, No. yy 3
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Ring stage: young, usually ring-
shaped malaria trophozoites growing
within host red blood cells, before
pigment is evident by microscopy.
Seasonal malaria
chemoprevention (SMC):
intermittent administration of full
treatment courses of an antimalarial
medicine during the malaria season
to prevent malarial illness.
Sporozoite: motile stage of the
malaria parasite that is inoculated by
a feeding female anopheline
mosquito and may cause infection.
Sulphadoxine-pyrimethamine
(SP): previously ﬁrst-line therapy prior
to widespread development of
resistance. Used as part of the
recommended regiment for seasonal
malaria chemoprevention (SMC) and
for intermittent preventative treatment
during pregnancy (IPTp).
Tafenoquine: drug in development
for the treatment of P. vivax.
Vector control: measures of any
kind against malaria-transmitting
mosquitoes intended to limit their
ability to transmit the disease.presence of infections towards the end of the ﬁrst trimester [56,57]. Recent results have
demonstrated the safety of artemisinin drugs during this period [58].
In the [23_TD$DIFF]past 5 years, there has been increasing interest in the use of community-based adminis-
tration of drugs as a means to clear the parasite reservoir. Typically referred to asmass drug
administration (MDA), this involves giving antimalarial drugs to the whole population regard-
less of infection status. This strategy has recently been recommended by theWHO for a series of
different use scenarios (http://www.who.int/malaria/publications/atoz/role-of-mda-for-malaria.
pdf?ua=1): ( [31_TD$DIFF]i) in low-transmission settings to clear the parasite reservoir and hence ‘accelerate’
towards elimination; ( [32_TD$DIFF]ii) in areas with high levels of drug resistance, also with the aim of
accelerating towards elimination; ([33_TD$DIFF]iii) in a time-limited manner to respond to epidemics or in
complex emergencies.
The aim of MDA is to clear parasites, reduce prevalence, and maintain these gains either to
reduce incidence during the upcoming transmission season, or to achieve a level of transmission
so low such that local elimination is possible. Therefore, an antimalarial suitable for MDA should
not only effectively clear parasites but also suppress the resurgence in transmission commonly
seen in the months following the intervention. The research community has focused on the role
of gametocytocidal drugs in such strategies [30], arguing that all onward transmission needs to
be interrupted. However, this argument is made from an individual perspective rather than
considering the impact on the population as a whole. [30_TD$DIFF]By contrast, modelling studies have
demonstrated that drugs with a longer prophylactic period are likely to have a greater effect in
reducing P. falciparum transmission by preventing all treated individuals from being reinfected
[23,36–39]. Whilst gametocytocidal activity can be beneﬁcial, the same modelling studies have
shown that this factor is less important, acting only to delay the resurgence by a few weeks. This
is because the reduction in population-level onwards infectivity due to the gametocytocidal
activity is small compared to the long-lasting onwards infectivity of the asymptomatic untreated
individuals in the population (Figure 1). Modelling has demonstrated that an ACT with an
additional mosquitocidal effect could increase the impact and sustain the reductions of an
MDA in both high- and low-transmission settings [42].
For P. vivax, however, MDAwith drugs that treat only blood-stage infection are predicted to have
only a transient effect, whilst addition of a liver-stage drug is predicted to be highly effective
[49,59,60]. This is due to the large effect at a population-level of relapsing infection [61].
Fewer modelling studies have examined the role of MDA in epidemic control or complex
emergencies. One study showed that MDA could play an important role in mitigating the effect
that Ebola virus disease had on access to healthcare and hence treatment of malaria during the
2014–15 epidemic in West Africa [62]. In this study the duration of prophylaxis of the drug again
was found to be more important than gametocytocidal activity. Another modelling study
demonstrated the cost-effectiveness of provision of antimalarials to Ebola case contacts
[63]. Both studies highlight the beneﬁt of models to guide malaria control in emergency
situations.
Tackling the Emergence of Drug Resistance
Assessing the risk of drug resistance to a particular compound is embedded in the antimalarial
drug development process from the preclinical phases [64]. Numerous mathematical models
have been used to quantify how different drug properties could inﬂuence both the emergence
and spread of resistance. A key measure is the ease with which resistance can develop in the
laboratory in parasite cultures exposed to suboptimal levels of the drug. This appears to
correlate to some extent with resistance in the ﬁeld, with, for example, atovaquone resistance
being easy to develop in the laboratory, and artemisinin [34_TD$DIFF] resistance relatively harder [64]. The4 Trends in Parasitology, Month Year, Vol. xx, No. yy
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clinical disease and asymptomac infecon
(A) (B) (C)Relave onwards infecousness over course of infecon
(compared to untreated clinical disease)
Populaon-level contribuon
to onwards infecon
∼5%
∼14%
High Low
Transmission
Untreated
clinical
disease
0.0
0
100
101
102
103
104
105
106
107
50
As
ex
ua
l p
ar
as
ite
 d
en
sit
y 
(p
ar
as
ite
s p
er
 μ
L)
100 150 200
Time (days)
0.2
0.4
0.6
0.8
1.0
Treated
clinical
disease
no GX
actvity
Treated
clinical
disease
ACT-like
GX actvity
Treated
clinical
disease
100% GX
actvity
Asymptomac
infecon
Untreated clinical disease
Key:
Treated clinical disease
Asymptomac infecon
Figure 1. Schematic of the Relationship between an Individual's Course of Infection, Their Contribution to the Population Infectious Reservoir and the
Impact of Treatment. Panel (A) shows a hypothetical typical course of infection for untreated and treated clinical disease (i.e., symptomatic infection) and asymptomatic
infection. The black horizontal line indicates the limit of detection for microscopy (200 parasites per mL). Panel (B) combines the duration of infection with the infectivity to
mosquitoes to produce a relative measure of onwards infectiousness for individuals with different types of infection and treatment based on parameter values presented in
[88]. We assume individuals with untreated clinical disease are highly infectious for 25 days, followed by a period of 200 days where they have patent asymptomatic
infection, then 100 days where they have subpatent asymptomatic infection. During these periods they are 65% and 9% as infectious as at their peak, respectively.
Individuals with clinical disease who are treated with a non-artemisinin combination therapy (ACT) with no gametocytocidal (GX) activity (dark blue) are assumed to remain
highly infectious for 25 days after treatment, whereas treatment with an ACT (medium blue) reduces the total duration to 10 days and the infectiousness after treatment to
9% of the pretreatment amount [22,40,88]. A drug with perfect GX activity (light blue) renders individuals instantly noninfectious after treatment [3_TD$DIFF] [22,24,25]. Panel (C)
considers the population-level contribution of untreated (red) and treated (dark blue) symptomatic and asymptomatic (orange) individuals based on the individual-level
durations of infection presented in (A) and the relative onwards infectiousness presented in (B). We assume that 80% of individuals with clinical disease are treated, and
that 30% of new infections are symptomatic in a high transmission setting and 60% in a low transmission setting [88]. Converting individual-level infectiousness to the
population level allows us to see that treated individuals only contribute 5% or 14% (high and low transmission settings respectively) to the total infectiousness of a
population. This indicates that improving the gametocytocidal activity of an antimalarial drug used for treatment [4_TD$DIFF] of symptomatic cases can only potentially impact a small
proportion of the total infectiousness of the population.probability of a particular combination of mutations occurring has been incorporated into
mathematical models, taking into account global numbers of cases to estimate a time until a
resistant strain begins to establish and spread somewhere in the world [65].
The PK/PD proﬁle of an antimalarial is another key determinant of the development of resistance.
Drugs with long half-lives are present in patients at suboptimal concentrations for a period of
time, and therefore there can be selection for partially resistant parasites when a patient is
exposed to new infections after being initially treated (Figure 2[35_TD$DIFF]A). Models can be used to
approximately quantify the length of this window of selection [66–70]. Partial resistance is often
an important step for the parasite on the pathway to higher grade resistance – for example, the
evolution of resistance to sulphadoxine-pyrimethamine (SP) – and can rapidly reduce the
duration of protection against reinfection. This reduction can be estimated using models where
direct clinical data are lacking [71], and is important for prophylactic interventions such as SMC.
However, some model outputs have highlighted the difﬁculties of using laboratory measures to
directly parameterise models of treatment in humans. For example, it has been shown that
estimates of the IC50 of several ACT partner drugs from the laboratory were very different from
those estimated from a within-host PK/PD model [72]. A review has suggested ways in which
such models could be further developed to improve their utility for drug development, for
example, by simultaneously including human immunity, parasite dynamics, stage-speciﬁcity
of drug action, and by ﬁtting to PK/PD data [15].Trends in Parasitology, Month Year, Vol. xx, No. yy 5
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Key Table
Table 1. Summary of the Relative Importance of the Different Drug
Properties for the Different Use Scenariosa
Property Refs
Clearance of
Blood-[17_TD$DIFF]Stage
[11_TD$DIFF]Parasites
Duration of
[18_TD$DIFF]Prophylaxis
Enhanced
[19_TD$DIFF]Gametocytocidal
[20_TD$DIFF]Activityb[16_TD$DIFF]
Mosquitocidal
[20_TD$DIFF]Activity
Hypnozoite
[20_TD$DIFF]Activityc
First-line treatment +++ ++ + + ++ [23,25,42,45,
46,49,50,61]
Chemoprevention:
children
+++ +++ ?? ?? ?? [44,52,89,90]
Chemoprevention:
pregnant women
+++ +++ ?? ?? ?? [56,57]
MDA: elimination ++ ++ + +++ +++ [36–39,42,60]
MDA: emergencies ++ ++ + ?? ?? [62,63]
aThe rankings are based on a review of the modelling literature with the key references shown in the ﬁnal column. +++ = very
important; ++ = moderately important; + = limited importance; ?? = further research required.
bEnhanced gametocytocidal activity refers to that greater than current ACTs.
cRelevant to Plasmodium vivax only.Another important source of selection pressure for partial resistance is low dosing (Figure 2[35_TD$DIFF]B),
which has been explored using mathematical models [73]. Suboptimal dosing can occur when
patients do not fully adhere to the treatment regimen, and therefore creating simple and short-
dose regimens is important. Synthetic artemisinins which are currently in development have
been designed to have longer half-lives, and therefore patients will likely require fewer than the
three doses of artemisinin currently given as part of most ACTs [74]. Suboptimal dosing can also(A)
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Figure 2. Pharmacokinetics and Vulnerable Time-Points for Selection of Partial Resistance. (A) During drug
elimination, the [5_TD$DIFF]unbroken line shows the drug concentration in the blood of a patient who takes the full course of a three-
dose drug regimen, which has a long elimination half-life and so its concentration wanes gradually over time. This schematic
is based on the antimalarial piperaquine. The window of selection is the time during which drug concentrations are
sufﬁciently high to allow partially resistant parasites to survive, but kill sensitive parasites (in between the horizontal [6_TD$DIFF]broken
lines). [7_TD$DIFF] uring [8_TD$DIFF]this [9_TD$DIFF]period, [10_TD$DIFF]this [11_TD$DIFF]selection [12_TD$DIFF]will [13_TD$DIFF]usually [14_TD$DIFF]act [15_TD$DIFF]on parasites from new infections. Above these concentrations (above
the upper [6_TD$DIFF]broken line), both sensitive and partially resistant parasites are killed by the drug, and below these concentrations
(below the lower [6_TD$DIFF]broken line), both sensitive and partially resistant parasites can survive, so there is no selection. The
window of selection would be longer for highly resistant parasites compared with parasites with a low level of partial
resistance. (B) The red line shows the drug concentration in the blood of a patient who receives a lower than recommended
amount of the drug, in this case because they take only one dose instead of three. Drug concentration therefore does not
remain at a high enough level for a sufﬁcient length of time to kill all parasites in the initial infection, potentially selecting for
partially resistant parasites.
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drug being prescribed for broad weight bands, or different metabolism of the drug in different
age groups [14,75]. Modelling, based on pharmacokinetic data, can be used to explore
alternative dosing guidelines and optimise drug concentrations across age and weight groups
[13,16]. One such analysis suggests that twice-daily rather than once-daily ACT doses could
improve drug efﬁcacy whilst keeping drug concentrations below potentially toxic levels [76].
Modelling can also explore hypotheses about how resistance evolves and spreads. For example,
given the observed mutation rate of P. falciparum, it was initially assumed that drug resistance to
chloroquine and SP had evolved many times independently. However, genetic data showed
that high-grade resistance had in fact evolved only a very small number of times, and then spread.
Mathematical modelling was able to reconcile these observations by quantifying bottlenecks for
resistant strains, not only during its initial evolution but then during onward transmission [77]. A
within-host model also helped to elucidate that artemisinin resistance was due to the ring stages
of the parasite becoming insensitive to the drug, before this was conﬁrmed in the laboratory [78].
Furthermore, novel hypotheses have been generated about whether using the minimum drug
dose required to be clinically effective could actually prevent the development of high-grade
resistance [79], though this is contradicted by results from other models [12].
A major advance in combating antimalarial drug resistance was made in the development and
adoption of artemisinin combination therapies [80,81]. The large reduction in the probability of
resistance developing when using two drugs simultaneously, relative to monotherapies, hasBox 1. Integrating PK/PD and Transmission Modelling Approaches
The PK/PD of antimalarials is typically well characterised in individuals with clinical infection, but less so in asymptomatic infections that also contribute to onward
infection. Information on both is required for assessment of drug candidates for drug-based strategies that target non-symptomatic individuals such as SMC andMDA,
as shown in Figure I. Once characterised, these can be directly incorporated in transmission models to estimate the impact in populations with varying levels of clinical
disease and asymptomatic infection.
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TREPAR 1557 No. of Pages 10been quantiﬁed in mathematical models [70,80,81]. However, the reduced killing of artemisinin-
resistant parasites by artemisinin derivatives increases the exposure of parasites to partner
drugs, and indeed piperaquine resistance has already been rapidly selected in areas of
Cambodia with artemisinin resistance [4]. Further advances in this ﬁeld are ongoing, with trials
of triple combination therapy underway in Cambodia (http://www.wwarn.org/working-together/
partner-projects/tracking-resistance-artemisinin-collaboration). Outputs from models had
highlighted a potential problem of mismatched PK/PD proﬁles in existing ACTs, where the
longer-acting partner drugs remain in the blood after the shorter-acting artemisinin derivatives
were cleared from the patient [67]. The current trials have therefore created triple therapies
consisting of an artemisinin derivative, plus either meﬂoquine and piperaquine, which are
active for a month or more, or lumefantrine and amodiaquine, which both have a prophylactic
period of2 weeks [46]. The triple combination design also harnesses an intriguing ﬁnding that a
mutation conferring resistance to one partner drug appears to confer sensitivity to the other
partner drug [82,83]. Modelling the impact of these triple combinations on resistance develop-
ment is an important area for future research. It has also been proposed that adding primaquine
to ACT could impede the spread of resistance, althoughmodelling found a relatively small beneﬁt
of such a strategy [37]. Another proposed strategy for resistancemanagement is use ofmultiple
ﬁrst line therapy (MFT) in populations. The results from different models suggest different
degrees of advantage or disadvantage of MFT over the current strategy of sequentially replacing
drugs when resistance develops [65,84–86]. For such questions, further modelling has a key role
to play, as it is difﬁcult to envisage how the hypothesis could ever be tested in the ﬁeld.
Future Role of Models to Guide Drug Development
There has been a rapid growth in the development and application of models to guide drug
development for antimalarials, including both PK/PD modelling to identify appropriate candi-
dates for development, and transmission models to guide drug deployment and use scenarios.
As outlined here, models are now being used to guide development of new compounds, to
improve dosing and adherence of existing compounds, and to inform appropriate deployment
strategies at the individual and population levels.
Despite this progress, there remains a lack of the population-level insight that can be obtained
from modelling embedded in the current research agenda for drug-based strategies. This is
perhaps best demonstrated by the example of the development of the research agenda for low-
dose primaquine. Despite consistent outputs across a range of modelling approaches demon-
strating the very small potential impact of adding this to existing ACTs, this agenda has been
vigorously pursued and many countries are now adopting this into policy [87]. Earlier integration
of modelling approaches would therefore be beneﬁcial.
A key area for further research is to integrate PK/PD and transmission modelling approaches
(see Outstanding Questions and Box 1). This should involve the integration of population-level
modelling in in vitro laboratory assessment of drug candidates as well as better characterisation
of PK/PD effects within the population-level models. Such an approach could enable a better
understanding of the potential role of new candidate drugs, alone and in combination, as well as
guide potential alternative deployment strategies.
Finally, with the ever-present threat of the spread of artemisinin- and ACT-resistance, there is a
pressing need to consider population-based strategies to reduce the spread of existing resistant
parasites and to delay the emergence of resistance to new compounds. Given the inherent
difﬁculty in testing such strategies in the ﬁeld, modelling will likely remain the only route through
which strategies such as MFT can be evaluated. This will require a better understanding of the
relationship between laboratory measures of resistance [1_TD$DIFF] and [36_TD$DIFF]PKPD [37_TD$DIFF]in [38_TD$DIFF]humans, and epidemio-
logical spread [39_TD$DIFF] of resistance.8 Trends in Parasitology, Month Year, Vol. xx, No. yy
TREPAR 1557 No. of Pages 10
Outstanding Questions
How can model [40_TD$DIFF]predictions be tested
empirically? To what extent can evi-
dence from programmatic deployment
be used to test [41_TD$DIFF]and validate transmis-
sion and PK/PD models?Acknowledgments
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